Phenotypes associated with this allele

• Allele Symbol: Zfp36^tm4.1Pjb
• Allele Name: targeted mutation 4.1, Paul J Blackshear
• Allele ID: MGI:5441582
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Zfp36^tm4.1Pjb/Zfp36^tm4.1Pjb Lyz2^tm1(cre)Ifo/Lyz2^+	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N	MGI:5441587

Genotype
MGI:5441587

cn1

• Allelic Composition: Zfp36^tm4.1Pjb/Zfp36^tm4.1Pjb; Lyz2^tm1(cre)Ifo/Lyz2⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

focal hepatic necrosis ( J:188677 )

• scattered foci of hepatic necrosis in LPS-treated mice

mortality/aging

mortality/aging ( J:188677 )

N • mice do not become sick enough to require euthanasia unlike Zfp36^tm1.2Xen homozygotes

immune system

enlarged spleen ( J:188677 )

• in some mice

• in LPS-treated mice

increased spleen weight ( J:188677 )

• modest at 3 to 4 months in female mice

increased circulating tumor necrosis factor level ( J:188677 )

• 110 fold in LPS-treated mice

enlarged lymph nodes ( J:188677 )

• in some mice

increased inflammatory response ( J:188677 )

• widespread inflammatory cell infiltrates in liver, kidney, and lung in LPS-treated mice

increased susceptibility to endotoxin shock ( J:188677 )

• LPS-treated mice exhibit dramatic signs of endotoxemia (lethargy, tachypnea, piloerection and decreased body temperature); elevated TNF serum levels; enlarged spleens and dilated small intestines, with widespread inflammatory cell infiltrates in liver, kidney, and lung; scattered foci of hepatic necrosis, glomerular hypercellularity, and pulmonary alveolitis; and 5-fold increase in serum alanine aminotransferase, a 2.2-fold increase in blood urea nitrogen, and a 3-fold increase in lactate dehydrogenase compared with control mice

arthritis ( J:188677 )

• mild interphalangeal arthritis and inflammation in 1 of 4 mice

alveolitis ( J:188677 )

• in LPS-treated mice

muscle

abnormal myocardium layer morphology ( J:188677 )

• mild inflammation and fibrosis in 3 of 4 mice at 8 months

homeostasis/metabolism

increased blood urea nitrogen level ( J:188677 )

• 2.2-fold in LPS-treated mice

increased circulating tumor necrosis factor level ( J:188677 )

• 110 fold in LPS-treated mice

increased circulating alanine transaminase level ( J:188677 )

• 5-fold in LPS-treated mice

increased circulating lactate dehydrogenase level ( J:188677 )

• 3-fold in LPS-treated mice

decreased body temperature ( J:188677 )

• dramatic in LPS-treated mice

behavior/neurological

lethargy ( J:188677 )

• dramatic in LPS-treated mice

abnormal pilomotor reflex ( J:188677 )

• dramatic in LPS-treated mice

respiratory system

alveolitis ( J:188677 )

• in LPS-treated mice

tachypnea ( J:188677 )

• dramatic in LPS-treated mice

cardiovascular system

abnormal myocardium layer morphology ( J:188677 )

• mild inflammation and fibrosis in 3 of 4 mice at 8 months

growth/size/body

decreased body weight ( J:188677 )

• at 6.5 months in female mice

• at 9 months in male mice

enlarged spleen ( J:188677 )

• in some mice

• in LPS-treated mice

increased spleen weight ( J:188677 )

• modest at 3 to 4 months in female mice

digestive/alimentary system

abnormal small intestine morphology ( J:188677 )

• dilated in LPS-treated mice

liver/biliary system

focal hepatic necrosis ( J:188677 )

• scattered foci of hepatic necrosis in LPS-treated mice

hematopoietic system

enlarged spleen ( J:188677 )

• in some mice

• in LPS-treated mice

increased spleen weight ( J:188677 )

• modest at 3 to 4 months in female mice

renal/urinary system

abnormal renal glomerulus morphology ( J:188677 )

• glomerular hypercellularity in LPS-treated mice

skeleton

arthritis ( J:188677 )

• mild interphalangeal arthritis and inflammation in 1 of 4 mice